Ipilimumab Improves Overall Survival in High-Risk Patients With Stage III Melanoma


24 ottobre 2016 - 22:29Rassegna stampa


After a median 5.3 years of follow-up in the EORTC 18071 trial, adjuvant ipilimumab was associated with a 28% reduction in the relative risk of death in high-risk patients with stage III melanoma, compared with placebo.

In the study, published simultaneously in the New England Journal of Medicine, 951 patients with completely resected disease were randomised in a double-blinded fashion to ipilimumab 10 mg/kg (induction and maintenance) or placebo. Patients were treated for up to 3 years or until disease progression, intolerable toxicity or withdrawal.

Five-year recurrence-free survival (RFS) was 41% in the ipilimumab arm and 30% in the placebo arm (hazard ratio [HR] = 0.76; 95% confidence interval [CI], 0.64-0.89; P = .0008). Overall survival was 65% for ipilimumab and 54% for placebo (HR = 0.72; 95% CI, 0.58-0.88; P = .001).

"Of course, this comes at a price in terms of side effects and toxicity," said Alexander Eggermont, MD, Gustave Roussy Institute, Villejui, France.

Grade 3/4 adverse events (AEs) that resulted in patients coming off treatment were gastrointestinal (16%), including colitis with fatal perforation in 3 patients, and hypophysitis in 4.4% (usually requiring lifelong hormone replacement therapy). The toxicity-related death rate was 1.1%. Overall, the immune-related grade 3/4 adverse event rates were 43% for ipilimumab and 2% for placebo.

Dr. Eggermont noted that ipilimumab superiority was consistent across all survival endpoints at 5 years, and that safety results long-term were also consistent with those in the primary report.

"Currently, adjuvant ipilimumab represents an important treatment option for patients with high-risk stage III melanoma," he said.

[Presentation title: Ipilimumab (IPI) vs Placebo (PBO) After Complete Resection of Stage III Melanoma: Final Overall Survival Results From the EORTC 18071 Randomized, Double-Blind, Phase 3 Trial. Abstract LBA2]

Inserito da segreteria SIDeMaST

La rassegna stampa contiene articoli di interesse dermatologico tratti da testate nazionali e non intende fornire una revisione critica né essere una fonte di notizie scientificamente validate. Si accettano (e sono bene graditi) commenti da parte dei soci esperti nel settore.

Lascia un commento sul sito e rispondi all'autore

I commenti sono soggetti a moderazione: non saranno pubblicati immediatamente ma dovranno essere approvati dalla segreteria.

Eventi SIDeMaST

Stato iscrizione